Top

Efficacy and Toxicity of ponatinib and 2nd generation TKI given after allogeneic SCT in Ph+ adult ALL.

Study number:

84210101

Type of transplant:

Allogeneic

Diseases:

Acute Lymphatic Leukaemia (ALL)

Short title:

TKI 2nd/mrd generation in Ph+ ALL

Study status:

Ongoing Data Collection

Deadline for data collection:

Study design:

Primary objective:

Key inclusion criteria:

Country:

Principal investigator:

Klaus HIRSCHBUEHL

Principal investigator email:

EBMT Study coordinator:

Mohamed HOUHOU

Study coordinator email:

mohamed.houhou@upmc.fr

Need help?

First Name

Last Name

Email address

CIC number

Area of interest

Message box

I understand and accept that my personal data will be used for communication concerning the submitted query or request.

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to data.protection@ebmt.org